Oncology Central

Deciding when to stop immunotherapy: exploring KEYNOTE-006 data

At the recent Annual Meeting of the American Society of Clinical Oncology (ASCO; 1–5 June 2018, IL, USA) meeting, data was presented highlighting the survival rates for patients who completed the KEYNOTE-006 Phase III study, for pembrolizumab given to unresectable or metastatic melanoma patients. It also gave insight on the follow up of patients who had a response. Of those who did the entire 2-year cycle of treatments, 86% remained without progressive disease 20 months after stopping.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.